Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 1016305, 8 pages
https://doi.org/10.1155/2017/1016305
Research Article

Identification of Pharmacologically Tractable Protein Complexes in Cancer Using the R-Based Network Clustering and Visualization Program MCODER

1Graduate Programs for Nanomedical Science, Yonsei University, Seoul, Republic of Korea
2Severance Biomedical Science Institute, Brain Korea 21 Plus Project for Medical Science, Yonsei University, College of Medicine, Seoul, Republic of Korea

Correspondence should be addressed to Hyun Seok Kim; ca.shuy@mikfsh

Received 3 March 2017; Revised 21 April 2017; Accepted 23 May 2017; Published 13 June 2017

Academic Editor: Xingming Zhao

Copyright © 2017 Sungjin Kwon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Ideker and R. Sharan, “Protein networks in disease,” Genome Research, vol. 18, no. 4, pp. 644–652, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Barabási, N. Gulbahce, and J. Loscalzo, “Network medicine: a network-based approach to human disease,” Nature Reviews Genetics, vol. 12, no. 1, pp. 56–68, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. J. T. Erler and R. Linding, “Network-based drugs and biomarkers,” Journal of Pathology, vol. 220, no. 2, pp. 290–296, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Fortney and I. Jurisica, “Integrative computational biology for cancer research,” Human Genetics, vol. 130, no. 4, pp. 465–481, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. A. R. Benson, D. F. Gleich, and J. Leskovec, “Higher-order organization of complex networks,” Science, vol. 353, no. 6295, pp. 163–166, 2016. View at Publisher · View at Google Scholar
  6. A. J. Enright, S. Van Dongen, and C. A. Ouzounis, “An efficient algorithm for large-scale detection of protein families,” Nucleic Acids Research, vol. 30, no. 7, pp. 1575–1584, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. G. D. Bader and C. W. V. Hogue, “An automated method for finding molecular complexes in large protein interaction networks,” BMC Bioinformatics, vol. 4, no. 1, p. 2, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Altaf-Ul-Amin, Y. Shinbo, K. Mihara, K. Kurokawa, and S. Kanaya, “Development and implementation of an algorithm for detection of protein complexes in large interaction networks,” BMC Bioinformatics, vol. 7, article 207, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. B. J. Frey and D. Dueck, “Clustering by passing messages between data points,” American Association for the Advancement of Science. Science, vol. 315, no. 5814, pp. 972–976, 2007. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  10. G. Liu, L. Wong, and H. N. Chua, “Complex discovery from weighted PPI networks,” Bioinformatics, vol. 25, no. 15, pp. 1891–1897, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. J. H. Morris, L. Apeltsin, A. M. Newman et al., “ClusterMaker: a multi-algorithm clustering plugin for Cytoscape,” BMC Bioinformatics, vol. 12, article 436, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Nepusz, H. Yu, and A. Paccanaro, “Detecting overlapping protein complexes in protein-protein interaction networks,” Nature Methods, vol. 9, no. 5, pp. 471-472, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Wang, J. Zhong, G. Chen, M. Li, F.-X. Wu, and Y. Pan, “ClusterViz: A Cytoscape APP for Cluster Analysis of Biological Network,” IEEE/ACM Transactions on Computational Biology and Bioinformatics, vol. 12, no. 4, pp. 815–822, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Li, Y. Tang, X. Wu, J. Wang, F.-X. Wu, and Y. Pan, “C-DEVA: Detection, evaluation, visualization and annotation of clusters from biological networks,” BioSystems, vol. 150, pp. 78–86, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Shannon, A. Markiel, O. Ozier et al., “Cytoscape: a software Environment for integrated models of biomolecular interaction networks,” Genome Research, vol. 13, no. 11, pp. 2498–2504, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Vaughan, J. I. Coward, R. C. Bast et al., “Rethinking ovarian cancer: recommendations for improving outcomes,” Nature Reviews Cancer, vol. 11, no. 10, pp. 719–725, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. R. G. Verhaak, P. Tamayo, J. Y. Yang et al., “Prognostically relevant gene signatures of high-grade serous ovarian carcinoma,” Journal of Clinical Investigation, vol. 123, no. 1, pp. 517–525, 2013. View at Google Scholar
  18. Cancer Genome Atlas Research Network, “Integrated genomic analyses of ovarian carcinoma,” Nature, vol. 474, no. 7353, pp. 609–615, 2011. View at Google Scholar
  19. R. W. Tothill, A. V. Tinker, J. George et al., “Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome,” Clinical Cancer Research, vol. 14, no. 16, pp. 5198–5208, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. X. Yin, X. Wang, B. Shen et al., “A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis,” Scientific Reports, vol. 6, Article ID 31079, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Zhang, T. Liu, and Z. Zhang, “Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer,” Cell, vol. 166, no. 3, pp. 755–765, 2016. View at Publisher · View at Google Scholar
  22. B. Zhang, J. Wang, and X. Wang, “Proteogenomic characterization of human colon and rectal cancer,” Nature, vol. 513, no. 7518, pp. 382–387, 2014. View at Publisher · View at Google Scholar
  23. D. Szklarczyk, A. Franceschini, S. Wyder et al., “STRING v10: protein-protein interaction networks, integrated over the tree of life,” Nucleic Acids Research, vol. 43, pp. D447–D452, 2015. View at Publisher · View at Google Scholar
  24. A. H. Wagner, A. C. Coffman, B. J. Ainscough et al., “DGIdb 2.0: mining clinically relevant drug–gene interactions,” Nucleic Acids Research, vol. 44, no. D1, pp. D1036–D1044, 2016. View at Publisher · View at Google Scholar
  25. S. D. Desai, A. L. Haas, L. M. Wood et al., “Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway,” Cancer Research, vol. 66, no. 2, pp. 921–928, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Musa, B. Pothuri, S. V. Blank et al., “Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer,” Gynecologic Oncology, vol. 144, no. 2, pp. 279–284, 2016. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Selvendiran, S. Ahmed, A. Dayton et al., “HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition,” Cancer Biology & Therapy, vol. 12, no. 9, pp. 837–845, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. Z. Duan, R. Y. Ames, M. Ryan, F. J. Hornicek, H. Mankin, and M. V. Seiden, “CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells,” Cancer Chemotherapy and Pharmacology, vol. 63, no. 4, pp. 681–689, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Roskoski, “Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs,” Pharmacological Research, vol. 107, pp. 249–275, 2016. View at Publisher · View at Google Scholar · View at Scopus
  30. A. R. Abdul Razak, M. Mau-Soerensen, N. Y. Gabrail et al., “First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors,” Journal of Clinical Oncology, vol. 34, no. 34, pp. 4142–4150, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Chen, S. C. Camacho, T. R. Silvers et al., “Inhibition of the nuclear export receptor XPO1 as a therapeutic target for platinum-resistant ovarian cancer,” Clinical Cancer Research, 2016. View at Google Scholar
  32. J. Kim, E. McMillan, H. S. Kim et al., “XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer,” Nature, vol. 538, no. 7623, pp. 114–117, 2016. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Ai, Z. Bie, S. Zhang, and A. Li, “Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment,” American Journal of Cancer Research, vol. 6, no. 8, pp. 1624–1635, 2016. View at Google Scholar · View at Scopus
  34. J. S. Desgrosellier and D. A. Cheresh, “Integrins in cancer: biological implications and therapeutic opportunities,” Nature Reviews Cancer, vol. 10, no. 1, pp. 9–22, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Seguin, J. S. Desgrosellier, S. M. Weis, and D. A. Cheresh, “Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance,” Trends in Cell Biology, vol. 25, no. 4, pp. 234–240, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Sawada, C. Ohyagi-Hara, T. Kimura, and K.-I. Morishige, “Integrin inhibitors as a therapeutic agent for ovarian cancer,” Journal of Oncology, Article ID 915140, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Xu, J. Lefringhouse, Z. Liu et al., “Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy,” Oncogenesis, vol. 6, no. 1, article e295, 2017. View at Publisher · View at Google Scholar
  38. Y. S. Hong, S.-W. Hong, S.-M. Kim et al., “Bortezomib induces G 2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1,” International Journal of Oncology, vol. 41, no. 1, pp. 76–82, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. M. de Toledo, C. Anguille, L. Roger, P. Roux, and G. Gadea, “Cooperative Anti-Invasive Effect of Cdc42/Rac1 Activation and ROCK Inhibition in SW620 Colorectal Cancer Cells with Elevated Blebbing Activity,” PLoS ONE, vol. 7, no. 11, Article ID e48344, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. F. De Sousa, E. Melo, X. Wang, and M. Jansen, “Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions,” Nature Medicine, vol. 19, no. 5, pp. 614–618, 2013. View at Publisher · View at Google Scholar
  41. A. Sadanandam, C. A. Lyssiotis, K. Homicsko et al., “A colorectal cancer classification system that associates cellular phenotype and responses to therapy,” Nature Medicine, vol. 19, no. 5, pp. 619–625, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. T. T. Vellinga, S. Den Uil, I. H. B. Rinkes et al., “Collagen-rich stroma in aggressive colon tumors induces mesenchymal gene expression and tumor cell invasion,” Oncogene, vol. 35, no. 40, pp. 5263–5271, 2016. View at Publisher · View at Google Scholar · View at Scopus